TY - JOUR
T1 - Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition
AU - for the Alzheimer's Disease Neuroimaging Initiative
AU - Wang, Gang
AU - Dong, Qunxi
AU - Wu, Jianfeng
AU - Su, Yi
AU - Chen, Kewei
AU - Su, Qingtang
AU - Zhang, Xiaofeng
AU - Hao, Jinguang
AU - Yao, Tao
AU - Liu, Li
AU - Zhang, Caiming
AU - Caselli, Richard J.
AU - Reiman, Eric M.
AU - Wang, Yalin
N1 - Funding Information:
This work was partially supported by National Natural Science Foundation of China ( 61772253 , 61771231 , 61873117 , 61872170 , 61903172 ); NSFC Joint Fund with Zhejiang Integration of Informatization and Industrialization under Key Project (U1609218); Key Research and Development Program of Shandong Province ( 2019JZZY010125 ); Shandong Province Higher Educational Science and Technology Program (J17KA050); National Institute on Aging ( RF1AG051710 , R21AG065942 , R01AG031581 , P30AG19610 ); National Institute of Biomedical Imaging and Bioengineering ( R01EB025032 ); and Arizona Alzheimer’s Consortium.
Funding Information:
This work was partially supported by National Natural Science Foundation of China (61772253, 61771231, 61873117, 61872170, 61903172); NSFC Joint Fund with Zhejiang Integration of Informatization and Industrialization under Key Project (U1609218); Key Research and Development Program of Shandong Province (2019JZZY010125); Shandong Province Higher Educational Science and Technology Program (J17KA050); National Institute on Aging (RF1AG051710, R21AG065942, R01AG031581, P30AG19610); National Institute of Biomedical Imaging and Bioengineering (R01EB025032); and Arizona Alzheimer's Consortium. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co. Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/1
Y1 - 2021/1
N2 - Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration biomarkers (UNB). However, existing UNB work either fails to model large group variances or does not capture AD dementia (ADD) induced changes. We propose a novel low-rank and sparse subspace decomposition method capable of stably quantifying the morphological changes induced by ADD. Specifically, we propose a numerically efficient rank minimization mechanism to extract group common structure and impose regularization constraints to encode the original 3D morphometry connectivity. Further, we generate regions-of-interest (ROI) with group difference study between common subspaces of Aβ+AD and Aβ−cognitively unimpaired (CU) groups. A univariate morphometry index (UMI) is constructed from these ROIs by summarizing individual morphological characteristics weighted by normalized difference between Aβ+AD and Aβ−CU groups. We use hippocampal surface radial distance feature to compute the UMIs and validate our work in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. With hippocampal UMIs, the estimated minimum sample sizes needed to detect a 25% reduction in the mean annual change with 80% power and two-tailed P=0.05are 116, 279 and 387 for the longitudinal Aβ+AD, Aβ+mild cognitive impairment (MCI) and Aβ+CU groups, respectively. Additionally, for MCI patients, UMIs well correlate with hazard ratio of conversion to AD (4.3, 95% CI = 2.3–8.2) within 18 months. Our experimental results outperform traditional hippocampal volume measures and suggest the application of UMI as a potential UNB.
AB - Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration biomarkers (UNB). However, existing UNB work either fails to model large group variances or does not capture AD dementia (ADD) induced changes. We propose a novel low-rank and sparse subspace decomposition method capable of stably quantifying the morphological changes induced by ADD. Specifically, we propose a numerically efficient rank minimization mechanism to extract group common structure and impose regularization constraints to encode the original 3D morphometry connectivity. Further, we generate regions-of-interest (ROI) with group difference study between common subspaces of Aβ+AD and Aβ−cognitively unimpaired (CU) groups. A univariate morphometry index (UMI) is constructed from these ROIs by summarizing individual morphological characteristics weighted by normalized difference between Aβ+AD and Aβ−CU groups. We use hippocampal surface radial distance feature to compute the UMIs and validate our work in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. With hippocampal UMIs, the estimated minimum sample sizes needed to detect a 25% reduction in the mean annual change with 80% power and two-tailed P=0.05are 116, 279 and 387 for the longitudinal Aβ+AD, Aβ+mild cognitive impairment (MCI) and Aβ+CU groups, respectively. Additionally, for MCI patients, UMIs well correlate with hazard ratio of conversion to AD (4.3, 95% CI = 2.3–8.2) within 18 months. Our experimental results outperform traditional hippocampal volume measures and suggest the application of UMI as a potential UNB.
KW - Alzheimer’ s disease
KW - Cox proportional hazard model
KW - Magnetic resonance imaging (MRI)
KW - Minimum sample size
KW - Subspace decomposition
KW - Univariate morphometry index
UR - http://www.scopus.com/inward/record.url?scp=85095457244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095457244&partnerID=8YFLogxK
U2 - 10.1016/j.media.2020.101877
DO - 10.1016/j.media.2020.101877
M3 - Article
C2 - 33166772
AN - SCOPUS:85095457244
SN - 1361-8415
VL - 67
JO - Medical Image Analysis
JF - Medical Image Analysis
M1 - 101877
ER -